Adjei Ernest K, Owusu-Afriyie Osei, Awuah Baffour, Stalsberg Helge
Department of Pathology, University Hospital of North Norway (UNN), Tromsø, Norway; Department of Pathology, Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana.
Breast J. 2014 May-Jun;20(3):308-11. doi: 10.1111/tbj.12261. Epub 2014 Apr 8.
Hormonal treatment of breast cancer is effective only in patients whose tumors express estrogen and/or progesterone receptors (ER, PR). Receptor assessment is often not available in low-resource areas, and the choice may be to apply endocrine therapy to all or none of breast cancer patients, depending on the proportion of patients that can be expected to respond. Fifty-one invasive breast cancers from Ghana and 100 from Norway diagnosed in the same laboratory during the same time period were reexamined in a blinded slide review. Of Ghanaian tumors, 76% were ER+ (≥1% ER+ tumor cells). Of Norwegian tumors, 85% were ER+. Triple-negative tumors were seen in 22% of Ghanaian patients and in 7% of Norwegian patients. A review of previous similar studies in sub-Saharan patients shows very discrepant results. Standardization and quality control of receptor assessment and well-designed clinical trials in sub-Saharan African breast cancer patients are needed to give a sound basis for endocrine treatment in this area.
乳腺癌的激素治疗仅对肿瘤表达雌激素和/或孕激素受体（ER、PR）的患者有效。在资源匮乏地区，通常无法进行受体评估，治疗选择可能是根据预期有反应的患者比例，对所有乳腺癌患者或不对任何患者进行内分泌治疗。对同一时期在同一实验室诊断的来自加纳的51例浸润性乳腺癌和来自挪威的100例浸润性乳腺癌进行了盲法玻片复查。加纳肿瘤中，76%为ER阳性（ER阳性肿瘤细胞≥1%）。挪威肿瘤中，85%为ER阳性。22%的加纳患者和7%的挪威患者为三阴性肿瘤。对撒哈拉以南地区患者此前类似研究的回顾显示结果差异很大。需要对受体评估进行标准化和质量控制，并在撒哈拉以南非洲乳腺癌患者中开展精心设计的临床试验，以便为该地区的内分泌治疗提供可靠依据。
